2. Search Result
Search Result
Results for "

delta activity

" in MedChemExpress (MCE) Product Catalog:

213

Inhibitors & Agonists

1

Fluorescent Dyes

5

Biochemical Assay Reagents

8

Peptides

3

Inhibitory Antibodies

29

Natural
Products

5

Isotope-Labeled Compounds

2

Oligonucleotides

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N6733
    Aphidicolin
    10+ Cited Publications

    		 DNA/RNA Synthesis HSV Apoptosis Antibiotic Orthopoxvirus Infection Inflammation/Immunology
    Aphidicolin is an inhibitor of DNA polymerase α and δ, prevents mitotic cell division by interfering DNA polymerase activity. Aphidicolin is an antibiotic produced by mold Cephalosporium aphidicola, inhibits cellular deoxyribonucleic acid synthesis and the growth of herpes simplex virus. Aphidicolin exhibits anti-orthopoxvirus activity and potentiates apoptosis induced by arabinosyl nucleosides in a human promyelocytic leukemia cell line .
    Aphidicolin
  • HY-15136
    Lonafarnib
    10+ Cited Publications

    Sch66336

    		 Farnesyl Transferase Ras Autophagy Infection Neurological Disease Cancer
    Lonafarnib (Sch66336) is a potent and orally active, and CNS-penetrant farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities .
    Lonafarnib
  • HY-B0719
    Ingenol Mebutate
    5 Publications Verification

    Ingenol 3-angelate; PEP005

    		 PKC Inflammation/Immunology Cancer
    Ingenol Mebutate is an active ingredient in Euphorbia peplus, acts as a potent PKC modulator, with Kis of 0.3, 0.105, 0.162, 0.376, and 0.171 nM for PKC-α, PKC-β, PKC-γ, PKC-δ, and PKC-ε, respectively, and has antiinflammatory and antitumor activity.
    Ingenol Mebutate
  • HY-P99043
    Rovalpituzumab
    1 Publications Verification

    SC-0001

    		 Notch Cancer
    Rovalpituzumab is a humanized monoclonal antibody against delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC) .
    Rovalpituzumab
  • HY-P1502
    β-Endorphin, human
    1 Publications Verification

    		 Opioid Receptor Neurological Disease
    β-Endorphin, human, a prominent endogenous peptide, existing in the hypophysis cerebri and hypothalamus, is an agonist of opioid receptor, with preferred affinity for μ-opioid receptor and δ-opioid receptor; β-Endorphin, human exhibits antinociception activity.
    β-Endorphin, human
  • HY-12879
    IWP-4
    2 Publications Verification

    		 Wnt Casein Kinase Cardiovascular Disease Neurological Disease Cancer
    IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure .
    IWP-4
  • HY-B0760
    Fenofibric acid
    3 Publications Verification

    FNF acid

    		 PPAR COX Metabolic Disease
    Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.
    Fenofibric acid
  • HY-127143
    Sterculic acid

    		Stearoyl-CoA Desaturase (SCD) Inflammation/Immunology
    Sterculic acid is a stearoyl-CoA desaturase-1 (SCD1) inhibitor. Sterculic acid specifically inhibits the delta-9 desaturase (Δ9D) activity with an IC50 value of 0.9 μM .
    Sterculic acid
  • HY-N0701
    (-)-Asarinin
    1 Publications Verification

    		 Apoptosis Reactive Oxygen Species (ROS) STAT Src Stearoyl-CoA Desaturase (SCD) Bacterial Infection Neurological Disease Inflammation/Immunology Cancer
    (-)-Asarinin is a tetrahydrofurofurano lignan with various biological activities. (-)-Asarinin induces apoptosis in cancer cells. (-)-Asarinin promotes mitochondrial ROS accumulation, inhibits the STAT3 signaling pathway and induces apoptosis in precancerous cells. (-)-Asarinin is a Src family kinase inhibitor that suppresses mast cell activation. (-)-Asarinin is a non-competitive Δ5-desaturase inhibitor with a Ki of 0.28 mM. (-)-Asarinin possesses pain relief, anti-viral, anti-allergic and anti-tuberculous bacilli, and anti-tumor effects .
    (-)-Asarinin
  • HY-117427
    D5D-IN-326
    2 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    D5D-IN-326 is a selective, orally active delta-5 desaturase (D5D) inhibitor, with IC50s of 72 and 22 nM for rat and human D5D in enzymic and cell-based assays, respectively, has no effect on D6D or D9D activity. D5D-IN-326 reduces insulin resistance and decreases body weight in diet-induced obese C57BL/6J mice .
    D5D-IN-326
  • HY-N6775
    Sonolisib
    1 Publications Verification

    PX-866

    		 PI3K Cancer
    Sonolisib (PX-866), an improved Wortmannin analogue, is an oral, irreversible, and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)). Antitumor activity .
    Sonolisib
  • HY-P4053
    Dalargin

    		Opioid Receptor Neurological Disease
    Dalargin is a potent δ-opioid receptor agonist. Dalargin mitigates Gentamicin (HY-A0276)-induced cell death. Dalargin shows nephroprotective effects on Gentamicin (HY-A0276A)-induced kidney injury. Dalargin shows antiulcer activity .
    Dalargin
  • HY-12235
    PI-3065
    4 Publications Verification

    		 PI3K Inflammation/Immunology Cancer
    PI-3065 is a potent inhibitor of PI3K p110δ, with IC50 and Ki values of 5 nM and 1.5 nM, and exhibits less potent activity against p110α, p110β, p110γ with IC50s of 910, 600, >10000 nM.
    PI-3065
  • HY-124346
    T-3364366
    1 Publications Verification

    		 Stearoyl-CoA Desaturase (SCD) Metabolic Disease
    T-3364366 is a reversible, slow-binding, thienopyrimidinone delta-5 desaturase (D5D) inhibitor with IC50s of 1.9 nM and 2.1 nM in HepG2 and RLN-10 cells, respectively. T-3364366 exhibits potent D5D (IC500=19 nM) inhibitory activity and excellent selectivity away from delta-6 desaturase (D6D, IC50=6200 nM) and delta-9 desaturase (stearoyl-CoA desaturase, SCD,50 >10000 nM) in the enzymatic activity assay .
    T-3364366
  • HY-W007626
    3,5-Dimethoxybenzaldehyde

    		Fungal Infection
    3,5-Dimethoxybenzaldehyde is an antifungal agent. 3,5-Dimethoxybenzaldehyde exhibits antifungal activity against Saccharomyces cerevisiae cell wall integrity mutants (slt2Δ and bck1Δ) and Aspergillus fumigatus MAPK mutants (sakAΔ and mpkCΔ) .
    3,5-Dimethoxybenzaldehyde
  • HY-17657
    Androst-5-enediol sulfate sodium

    5-Androstenediol 3-sulfate sodium

    		 Drug Intermediate Metabolic Disease
    Androst-5-enediol sulfate (5-Androstenediol 3-sulfate) sodium salt is an adrenal Δ5-steroid sulfate that synthesized by zona reticularis of adrenal depending on the lyase and Cytochrome b5 type A (CYB5A) activity. Androst-5-enediol sulfate sodium salt is a precursor hormone and can be desulfated to produce more potent androgens, including testosterone, in peripheral tissues like skin and liver. The serum level of Androst-5-enediol sulfate sodium salt has an age-related increase .
    Androst-5-enediol sulfate sodium
  • HY-120613
    BMS-986187

    		Opioid Receptor Neurological Disease
    BMS-986187 is an δ-opioid receptor-selective positive allosteric modulator (PAM) with an EC50 of 0.03 μM and a pKB of 6.02 (～1 μM). BMS-986187 has no observable PAM activity at the μ-receptor (EC50=3 μM) .
    BMS-986187
  • HY-13044
    ADL-5859 hydrochloride
    1 Publications Verification

    		 Opioid Receptor Potassium Channel Cytochrome P450 Neurological Disease Inflammation/Immunology
    ADL-5859 hydrochloride (compound 20) is a selective and orally active δ opioid receptor (DOR) agonist with an Ki and an EC50 value of 0.84 and 20 nM, respectively. ADL-5859 hydrochloride also shows inhibitory activity to hERG channel with an IC50 value of 78 μM. ADL-5859 hydrochloride can be used for the research of pain .
    ADL-5859 hydrochloride
  • HY-P1596
    Gluten Exorphin C

    		Opioid Receptor Neurological Disease
    Gluten exorphin C is an opioid peptide derived from wheat gluten. Its IC50 values are 40 μM and 13.5 μM for μ opioid and δ opioid activities in the GPI and MVD assays, respectively.
    Gluten Exorphin C
  • HY-104006
    CYM51010

    		Opioid Receptor Neurological Disease
    CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC50 of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .
    CYM51010
  • HY-116247
    ST247

    		PPAR Metabolic Disease Inflammation/Immunology
    ST247 a potent PPARβ/δ inverse agonist. ST247 has a higher affinity to PPARβ/δ. ST247 modulates expression of the activation marker CCL2 in the opposite direction. ST247 efficiently induces the interaction with corepressors. ST247 inhibits the agonist-induced transcriptional activity of PPARβ/δ .
    ST247
  • HY-103520
    DS2

    		GABA Receptor Neurological Disease
    DS2 is a selective positive allosteric modulator of δ-GABAA receptor. DS2 selectively potentiates GABA responses mediated by α4β3δ receptor. DS2 does not enhance activity at α4β3γ2 and α1β3γ2 receptors. DS2 relieves pain and has the potential for sleep disorders research .
    DS2
  • HY-N7506
    13-Hydroxyisobakuchiol

    delta3,2-Hydroxylbakuchiol

    		 Monoamine Transporter Dopamine Transporter Neurological Disease
    13-Hydroxyisobakuchiol (Delta3,2-Hydroxylbakuchiol), an analog of Bakuchiol (HY-N0235) that can be isolated from Psoralea corylifolia (L.), is a potent selective monoamine transporter inhibitor. 13-Hydroxyisobakuchiol is more selective for the dopamine transporter (DAT) (IC50 = 0.58 μM) and norepinephrine transporter (NET) (IC50 = 0.69 μM) than for the serotonin transporter (SERT) (IC50 = 312.02 μM). 13-Hydroxyisobakuchiol increases the activity of intact mice and improves the decreased activity of reserpinized mice in vivo. 13-Hydroxyisobakuchiol can be used for the research of disorders such as Parkinson's disease and depression .
    13-Hydroxyisobakuchiol
  • HY-106547
    Rilmazafone

    		GABA Receptor Neurological Disease
    Rilmazafone (450191S) is an orally active sleep inducer. Rilmazafone targets cytochrome P-450b and cytochrome P-450e. Rilmazafone induces hepatic drug-metabolizing enzyme activity in rats, mice and dogs. Rilmazafone is applicable for insomnia-related research .
    Rilmazafone
  • HY-117720
    OSU-2S

    		PKC Apoptosis Cancer
    OSU-2S is a potent PKCδ activator. OSU-2S inhibits cell proliferation and migration. OSU-2S decreases the expression of p-ERK1/2, increases the expression of PKCδ (38 kDa) when combined with Sorafenib (HY-10201). OSU-2S induces Apoptosis. OSU-2S slao is a non-immunosuppressive analogue of FTY720. OSU-2S shows anticancer activity .
    OSU-2S
  • HY-15505
    RWJ-67657

    JNJ 3026582

    		 p38 MAPK Cardiovascular Disease Inflammation/Immunology Cancer
    RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor with IC50s of 1 and 11 μM, respectively. RWJ-67657 displays no activity at p38γ and p38δ, and exhibits cardio protective effect. Anti-inflammatory and anti-tumor activity .
    RWJ-67657
  • HY-147419
    Vulolisib

    		PI3K Cancer
    Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC50 values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .
    Vulolisib
  • HY-101307
    BNTX maleate

    7-Benzylidenenaltrexone maleate

    		 Opioid Receptor Neurological Disease
    BNTX (7-Benzylidenenaltrexone) maleate is a δ1-opioid receptor antagonist with the Kis of 0.1, 10.8, 13.3, and 58.6 nM for δ1, δ2-, μ-, and κ-opioid receptor, respectively. BNTX maleate shows antinociceptive activity .
    BNTX maleate
  • HY-176239
    PROTAC PI3Kδ degrader-1

    		PROTACs PI3K Akt Apoptosis Autophagy Cancer
    PROTAC PI3Kδ degrader-1 is a Lysine-targeted covalent PI3Kδ PROTAC degrader with a DC50 of 3.98 nM. PROTAC PI3Kδ degrader-1 has a potent antiproliferative activity and selective PI3Kδ inhibition (IC50: 8 nM). PROTAC PI3Kδ degrader-1 also significantly degrades p-AKT, induces cell cycle arrest in G1 phase and prompts cell apoptosis and autophagy. PROTAC PI3Kδ degrader-1 effectively inhibits the tumor growth in SU-DHL-6 xenograft mice model . Pink: PI3Kδ ligand (HY-169983); Blue: VHL ligase ligand (HY-112078); Black: linker (HY-W013381)
    PROTAC PI3Kδ degrader-1
  • HY-170879
    JD123

    		p38 MAPK JNK Cancer
    JD123 inhibits JNK1 activity and the expression of cJun (1-135). JD123 is a ATP-competitive p38-γ MAPK inhibitor, but not effect to ERK1, ERK2, or p38-α, p38-β or p38-δ. .
    JD123
  • HY-W102516
    6-Dehydroprogesterone

    Δ6-Progesterone

    		 Endogenous Metabolite Others
    6-Dehydroprogesterone (Δ6-Progesterone) is a steroid compound that can be found in Botryodiplodia theobromae. 6-Dehydroprogesterone is a metabolic product of Progesterone (HY-N0437) after a microbial dehydrogenation reaction. 6-Dehydroprogesterone can be used to study steroid metabolism pathways, microbial dehydrogenase activity, and the biotransformation of steroids .
    6-Dehydroprogesterone
  • HY-174366
    JMC14

    		c-Fms PI3K Cancer
    JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC50 values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity .
    JMC14
  • HY-15136B
    (Rac)-Lonafarnib

    Sch66336 racemate

    		 Farnesyl Transferase Infection Cancer
    (Rac)-Lonafarnib (Sch66336 racemate) is the racemate of Lonafarnib. Lonafarnib is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities .
    (Rac)-Lonafarnib
  • HY-130120
    HWL-088

    		Free Fatty Acid Receptor PPAR Metabolic Disease
    HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC50 of 18.9 nM) with moderate PPARδ activity (EC50 of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .
    HWL-088
  • HY-169867
    BNTX

    7-Benzylidenenaltrexone

    		 Opioid Receptor Neurological Disease
    BNTX (7-Benzylidenenaltrexone) is a highly selective δ1 opioid receptor antagonist. BNTX selectively antagonizes the antinociceptive activity mediated by spinal δ1 opioid receptors, and does not alter the antinociceptive effects mediated by δ2, μ or κ opioid receptors at selective doses .
    BNTX
  • HY-106809
    BMY-21502

    BMS-181168

    		 Drug Derivative Neurological Disease
    BMY-21502 (BMS-181168) is a pyrrolidinone derivative with memory- and cognition-enhancing activities. BMS-181168 attenuates hypoxia-induced deterioration in brain function, as delta/theta decreases, alpha activity increases and the centroid of the combined delta/theta waves is accelerated .
    BMY-21502
  • HY-W127407
    Glycerophospho-N-arachidonoyl ethanolamine

    		Biochemical Assay Reagents Others
    Glycerophospho-N-Arachidonoyl Ethanolamine is a N-acylated ethanolamines (NAEs). Most NAEs are naturally occurring lipids with diverse biological activities. Different types of NAE can be derived from glycerophosphate-linked precursors through the activity of glycerophosphodiesterase 1 (GDE1). Glycerophosphate-N-Arachidonoyl Ethanolamine is the precursor of Anandamide (AEA), also known as Anandamide. AEA is an endocannabinoid neurotransmitter that binds to central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. It inhibits the specific binding of [3H]-HU-243 to synaptosomal membranes with a Ki value of 52 nM compared to 46 nM for δ9-THC.
    Glycerophospho-N-arachidonoyl ethanolamine
  • HY-19231
    DPI-3290

    Org 41793

    		 Opioid Receptor Neurological Disease
    DPI-3290 (Org 41793) is a potent and specific opioid receptors agonist with Ki values of 0.18 nM, 0.46 nM, and 0.62 nM for δ-, μ-, and κ-opioid receptors, respectively. DPI-3290 is one of a series of novel centrally acting agents with potent antinociceptive activity .
    DPI-3290
  • HY-W013852
    PKC-IN-6

    		Ser/Thr Kinase Tyrosinase PKA PKC EGFR Cancer
    PKC-IN-6 (Compound 21) is a selective inhibitor of tyrosine and serine kinases. PKC-IN-6 shows inhibitory activity against PKC-α, PKC-δ, PKA, EGF-R with IC50 values of 240, >500, >500, >100 μM, respectively. PKC-IN-6 is promising for research of cancers .
    PKC-IN-6
  • HY-N16459
    Albomycin δ1

    		Antibiotic Bacterial Infection
    Albomycin δ1 is a selective bacterial ribosome-targeted antibiotic (MIC: 0.0625 μg/mL against S. pneumoniae). Albomycin δ1 exerts bactericidal activity via covalent binding to 70S ribosomes and irreversible inhibition of peptidyl transferase. Albomycin δ1 is promising for research of S. pneumoniae and S. aureus infections .
    Albomycin δ1
  • HY-116257
    GSK-7227

    		PPAR PDHK Carnitine Palmitoyltransferase (CPT) Others
    GSK-7227 (compound 32) is a PPARδ partial agonist with the activity of regulating the expression of related genes. GSK-7227 has partial agonist effects on PPARδ target genes CPT1a and PDK4 in skeletal muscle cells.
    GSK-7227
  • HY-59024
    δ-Carboline

    		Drug Intermediate Infection Cancer
    δ-Carboline is a nitrogen-containing heterocyclic compound, and its derivatives all exhibit anti-cancer and antibacterial activities .
    δ-Carboline
  • HY-170859A
    AH081

    		PROTACs Casein Kinase Cancer
    AH081 (Compound 38) is a CK1δ/ε PROTAC degrader. AH081 is the negative control compound of AH078 (HY-170859). AH081 has inhibitory but no degradation activity for CK1δ/ε by using an inactive stereoisomer of the VHL ligand . Pink: CK1δ/ε ligand (HY-148251); Blue: VHL ligase ligand (HY-125845B); Black: linker
    AH081
  • HY-P1617
    LY 190388

    		Endogenous Metabolite Neurological Disease
    LY 190388 is a penicillamine-containing enkefa peptide analog with μ receptor agonist activity. LY 190388 showed analgesic effect in inhibiting the writhing response in mice after intracerebroventricular administration. The analgesic effect of LY 190388 is not caused by its δ receptor agonist action, but by its μ receptor agonist activity. When LY 190388 is used together with the δ receptor antagonist ICI 174864, an additive analgesic effect is produced .
    LY 190388
  • HY-174396
    PI3Kδ/HDAC6-IN-1

    		PI3K HDAC Bcl-2 Family Caspase Reactive Oxygen Species (ROS) Apoptosis Histone Methyltransferase Microtubule/Tubulin Cancer
    PI3Kδ/HDAC6-IN-1 (Compound 22E) is an orally active and dual inhibitor of PI3Kδ and HDAC6 with IC50 values of 2.4 nM and 6.2 nM, respectively. PI3Kδ/HDAC6-IN-1 exhibits potent antiproliferative effects on non-Hodgkin lymphoma (NHL) cells and possesses in vivo antitumor activity without significant toxicity. PI3Kδ/HDAC6-IN-1 arrests the cell cycle at the G0/G1 phase and induces apoptosis. PI3Kδ/HDAC6-IN-1 blocks the PI3K/AKT/mTOR signaling pathway and increases the acetylation levels of α-tubulin and histone H3 .
    PI3Kδ/HDAC6-IN-1
  • HY-101317A
    TAN-67

    SB-205607

    		 Opioid Receptor Metabolic Disease
    TAN-67 (SB-205607) is a non-peptidic delta-opioid receptor agonist that exhibits significant antinociceptive activity in both diabetic and non-diabetic mice. TAN-67 demonstrates a marked and dose-dependent reduction in acetic acid-induced abdominal constrictions, with a notably stronger effect in diabetic mice compared to their non-diabetic counterparts. TAN-67's antinociceptive properties are primarily mediated through the activation of delta 1-opioid receptors, as indicated by the pronounced antagonism observed upon administration of a selective delta 1-opioid receptor antagonist.
    TAN-67
  • HY-N3841B
    (Rac)-δ-Viniferin

    		Cytochrome P450 Neurological Disease
    (Rac)-δ-Viniferin is a racemate of δ-Viniferin (HY-N3841A), an isomer of ε-Viniferin (HY-N3841). ε-Viniferin (epsilon-Viniferin), the dimer of Resveratrol, displays a potent inhibitory effect for all the CYP activities, with Ki values from 0.5-20 μM. ε-Viniferin possesses potent antioxidant, anti-inflammatory, anti-diabetic, and anti-neurodegenerative capacity .
    (Rac)-δ-Viniferin
  • HY-17618A
    Rac-Pemafibrate

    Rac-K13675

    		 PPAR Inflammation/Immunology
    Pemafibrate racemate (K13675 racemate) is the racemate of pemafibrate, and activates PPARα activity, with EC50s of 1 nM, >10 μM and 1.7 μM for h-PPARα, h-PPARγ and h-PPARδ, respectively.
    Rac-Pemafibrate
  • HY-15136R
    Lonafarnib (Standard)

    Sch66336 (Standard)

    		 Reference Standards Farnesyl Transferase Ras Autophagy Infection Cancer
    Lonafarnib (Standard) is the analytical standard of Lonafarnib. This product is intended for research and analytical applications. Lonafarnib (Sch66336) is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.
    Lonafarnib (Standard)
  • HY-125141
    δ-CEHC

    		Endogenous Metabolite Inflammation/Immunology
    δ-CEHC is a δ-tocopherol (HY-113026) metabolite. δ-CEHC has antioxidant activity .
    δ-CEHC

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: